Kidney News Is Published by the American Society of Nephrology October 22 at 10:00 A.M
Total Page:16
File Type:pdf, Size:1020Kb
Y WE E E K N E D I D K I T I N O October/November 2020 | Vol. 12, Number 10 & 11 Scrutiny Continues Over Use of Race in Estimated GFR By Eric Seaborg s calls for social justice and unrest reach into at risk for kidney disease,” Delgado said. “We have also been every corner of American life, the controversy charged with recognizing that any change in eGFR report- over the inclusion of race as a factor in calculat- ing must consider multiple social and clinical implications, ing estimated glomerular filtration rates reached be based on rigorous science, and be part of a national con- Amore milestones as ASN and the National Kidney Foun- versation about uniform reporting across healthcare systems. dation (NKF) formed a task force to reassess the practice, Those are just two of the five charges that we have gotten.” a congressional committee chair sought information from The task force includes 14 members with broad exper- medical societies about the use of race in clinical algorithms, tise in healthcare disparities, epidemiology, health services and more institutions moved away from the practice. research, genetic ancestry, clinical chemistry, patient safety The issue even hit the mainstream media with a story and performance improvement, pharmacology, and social from Consumer Reports, “Medical Algorithms Have a Race sciences, as well as two patients. Problem.” The recommendations will be vetted by an eGFR Advi- The NKF-ASN Task Force on Reassessing the Inclu- sory Board, Delgado said, and “go through a series of checks sion of Race in Diagnosing Kidney Disease is co-chaired by members of the nephrology community at large, includ- by Cynthia Delgado, MD, and Neil R. Powe, MD, MPH, ing patients and patient advocacy groups, to make sure that MBA. Delgado is an associate professor of medicine at the we are all in agreement with what we recommend.” University of California, San Francisco, where Powe is also a “We have been diligently working on this for months,” professor of medicine. Delgado said. She noted that ASN has been playing a “key Formed in August, the task force has begun its delibera- behind the scenes role on efforts to promote diversity, eq- uity, and inclusion among kidney health professionals and tions and plans to issue its initial recommendations by the to work toward eliminating health disparities in the com- end of 2020. munities that we serve.” “We have been charged with examining the inclusion of race in the estimation of GFR and its implications for the diagnosis and subsequent management of patients with or Continued on page 6 > Kidney Week Scientific Sessions THURSDAY SATURDAY Inside Human Genome Editing: Responsible Pathway Forward Global Efforts to Curate the Genome State-of-the-Art Lecture: Victor J. Dzau, MD State-of-the-Art Lecture: Heidi Rehm, PhD Preparing for a Tubular Cell Metabolic Reprogramming in Renal Fibrogenesis How the Unknown Unknowns Cause the Increased COVID-19 Surge Barry M. Brenner, MD, Endowed Lectureship: Peripheral Vascular Resistance Katalin Susztak, MD, PhD Robert W. Schrier, MD, Endowed Lectureship: Scarce Resources Report urges Kidney Care and the COVID-19 Experience Friedrich (Fred) C. Luft, MD nephrologists to take the lead in planning : Nicole (Nicki) Lurie, MD, MSPH Christopher R. Blagg Endowed Lectureship From Genes to Medicines: The Arc of Discovery Drug Targeting of the Podocyte Actin Cytoskeleton for Kidney Diseases Diabetic Kidney Disease Michelle P. Winn, MD, Endowed Lectureship: Mario Schiffer, MD, MBA Donald W. Seldin Young Investigator Award: Gut microbiota and diabetes, the Anna Greka, MD, PhD Managing Electrolyte Abnormalities on Continuous Renal DKD pandemic, and use of SGLT2s Replacement Therapy (CRRT) in solid organ transplant and AKI Burton D. Rose, MD, Endowed Lectureship: Ashita Tolwani, MD, MSc SUNDAY RNA Biology and Medicine: A Journey Clinical Trials FRIDAY of Unexpected Discovery Reducing Physician Distress: Organizational Approaches State-of-the-Art Lecture: Joan A. Steitz, PhD Patients as partners: why wait? to Improve Physician Well-Being Developing Actionable Patient Safety Outcome State-of-the-Art Lecture: Tait D. Shanafelt, MD Metrics for Dialysis Detective Nephron Celeste Castillo Lee Memorial Lectureship: Rationale for Personalized Medicine Approaches Allison Tong, PhD, MPH A case of type 2 diabetes mellitus with to the Management of CKD-Associated Osteoporosis an elevated hemoglobin A1c Jack W. Coburn, MD, Endowed Lectureship: Presentation of ASN Awards Glenn M. Chertow, MD, MPH Understanding Cellular Oxygen-Sensing Mechanisms: Implications for Medicine Homer W. Smith Award Lecture: Sir Peter John Ratcliffe B:11" T:10.5" S:9.5" COMING SOON KidneyNews For Intravenous Infusion During Hemodialysis A New Way to Deliver Bioavailable Iron and Stabilize Hemoglobin.* *In 2 phase 3 clinical studies, Hgb values remained stable at baseline levels in TRIFERIC patients while Hgb concentration declined in placebo-treated patients. 1 S:13.25" T:14.5" B:15" Sign up for an exclusive TRIFERIC AVNU Evaluation Program! Visit TRIFERIC.com/evaluation to enroll and be among the first clinicians to use TRIFERIC AVNU. Please see full Prescribing Information at TRIFERICAVNU.com. INDICATION AND USAGE hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. TRIFERIC® AVNU (ferric pyrophosphate citrate injection) is indicated for Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients the replacement of iron to maintain hemoglobin in adult patients with receiving ferric pyrophosphate citrate in two randomized clinical trials. hemodialysis-dependent chronic kidney disease (HDD-CKD). Limitations of use: TRIFERIC AVNU is not intended for use in patients Iron status should be determined on pre-dialysis blood samples. Post dialysis receiving peritoneal dialysis. TRIFERIC AVNU has not been studied in patients serum iron parameters may overestimate serum iron and transferrin saturation. receiving home hemodialysis. Adverse Reactions Most common adverse reactions (incidence ≥3% and at least 1% greater IMPORTANT SAFETY INFORMATION than placebo) in controlled clinical studies include: headache, peripheral Warnings and Precautions edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site Serious hypersensitivity reactions, including anaphylactic-type reactions, hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in some of which have been life-threatening and fatal, have been reported in extremity, back pain, and dyspnea. patients receiving parenteral iron products. Patients may present with shock, Reference: 1. Fishbane SN, Singh AK, Cournoyer SH, et al. Ferric pyrophosphate citrate clinically significant hypotension, loss of consciousness, and/or collapse. (Triferic®) administration via the dialysate maintains hemoglobin and iron balance in chronic Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis patients. Nephrol Dial Transplant. 2015;30(12):2019-2026. TRIFERIC and TRIFERIC AVNU are registered trademarks of Rockwell Medical, Inc. © 2020 Rockwell Medical, Inc. All rights reserved. US-AVNU-20-HCP-00004 09/2020 KidneyNews EDITORIAL STAFF Editor-in-Chief: Richard Lafayette, MD Executive Editor: Dawn McCoy ASN Kidney Week— Design: Lisa Cain EDITORIAL BOARD New in 2020 Joseph Mattana, MD, St. Vincent’s Medical Center, Bridgeport, CT Andrew King, MD, Scripps, San Diego, CA Kidney Week Reimagined: A Fully Digital Meeting Vivek Kumar, MD, Post Graduate Institute of Medical Education and Research, Chandigarh, India ASN has been honored to host the world’s premier meeting in nephrol- Pascale Lane, MD, FASN, University of Oklahoma Health Sciences Edgar V. Lerma, MD, FASN, University of Illinois – Chicago / ogy for 50+ years. While we have all enjoyed the various sites at which Advocate Christ Medical Center, Oak Lawn, IL past annual meetings have taken place, Kidney Week has not succeed- Gert Mayer, MD, Medical University of Innsbruck ed because of a specific location. Uday S. Nori, MD, Ohio State University Wexner Medical Center Glenda Payne, MS, RN, CNN, Nephrology Clinical Solutions This year’s meeting is offered in a fully online format with educational Jeffrey Petersen, MD, Amgen Amy Williams, MD, Mayo Clinic, Rochester, MN presentations delivered live-streamed, simulive, and on-demand; ePost- Fellows Corner: Sam Kant and Harini Bejjanki ers; digital exhibit hall; virtual networking opportunities; and more. An- nual Meeting content will launch October 22, recorded, and will be avail- ADVERTISING SALES able on the meeting website through December 4. The Walchli Tauber Group 2225 Old Emmorton Road, Suite 201, Bel Air, MD 21015 Questions? Check out FAQs, or email [email protected]. 443-252-0571 Mobile 214-704-4628 Phone Early Programs [email protected] ASN is hosting five Early Programs this year, preceding the Annual Meet- CLASSIFIED ADVERTISING ing. For each program, on-demand presentations will be available start- 443-512-8899 *106 ing October 14, and live-streamed sessions will take place October [email protected] 19–21. ASN COUNCIL • Advances in Research Conference: Single-Cell Biology President: Anupam Agarwal, MD, FASN • Basic Research Forum for Emerging Kidney Scientists: President-elect: Susan E. Quaggin, MD A Partnership Between APS and ASN Past-President: Mark E. Rosenberg, MD, FASN Secretary-Treasurer: Keisha L. Gibson, MD, MPH • Critical Care Nephrology: